If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynectics Regulatory News (SNX)

Share Price Information for Synectics (SNX)

Share Price is delayed by 15 minutes
Get Live Data
200.00    0.00 (0.00%)
Bid:
195.00
Ask:
205.00
Spread: 10.00 (5.128%)
Market Cap: £34.01m
SNX Live PriceLast checked at - London Stock Exchange

Intraday Synectics Share Chart

Director/PDMR Shareholding

8 Mar 2019 15:59

RNS Number : 3629S
Synectics PLC
08 March 2019
Β 

Synectics plc

(the "Company" or the "Group")

Β 

Award of Options under Share Plan

Β 

Directorate / PDMR Shareholding

Β 

8 March 2019

Β 

Synectics plc (AIM: SNX), a leader in the design, integration, control and management of advanced surveillance technology and networked security systems, announces thatΒ on 7 March 2019 it made awards over 65,000 Synectics plc ordinary shares of 20p (the "Shares") to certain Persons Discharging Managerial Responsibility ("PDMRs"), under its Performance Share Plan ("PSP"), as detailed below:

Β 

Β 

Name

Position

Status

PSP award (number of Shares)

Paul Webb

Chief Executive

Executive Director

25,000

Simon Beswick

Finance Director

Executive Director

20,000

David Lowe

Business Strategy Director

PDMR

20,000

Β 

Following these awards, their total interests in SharesΒ comprise:

Β 

Β Name

Β Shares held

Interest in Shares in Synectics plc share schemes

Resultant total interest in Shares

% of issued share capital

Paul Webb

36,322

276,923

313,245

1.76

Simon Beswick

-

20,000

20,000

0.11

David Lowe

10,000

20,000

30,000

0.17

Β 

Under the PSP, selected employees are entitled to exercise an option to receive a certain number of Shares at any time after a 3 year vesting period, at no cost to themselves. The number of Shares that are awarded at the end of the 3 year period is dependent on the achievement of certain performance criteria.

Β 

Vesting of the PSP awards is dependent on the total return on Shares compared with the AIM All Share Total Return Index (the "Index"). If the total return on Shares out-performs the Index by 5% or more in the 3 years following the award, all of the Shares awarded will vest. If Shares match the Index performance, then 25% of the awarded Shares will vest. Between these points the number of Shares that vest will be pro-rata. If the total return on Shares underperforms the Index, then no Shares will vest. The limit on the number of Shares over which interests may be awarded remains unchanged.

Β 

Any entitlement under the PSP will lapse on cessation of employment prior to the end of the 3 year vesting period, unless cessation of employment is by reason of redundancy, ill health or death.

Β 

Should the performance criteria be met in full or part, it is intended that the appropriate number of Shares will be satisfied from unallocated Shares already held within the Company's employee benefit trust.

Β 

Full details of the PSP were set out in the Company's Annual Report for the year ended 30 November 2017.

Β 

For further information, please contact:

Β 

Synectics plc

Claire Stewart, Company Secretary

Tel: +44(0) 114 255 2509

Β 

Stockdale Securities

Tom Griffiths / Henry Willcocks

Tel: +44Β (0) 20 7601 6100

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
DSHEASDPESKNEFF
Date   Source Headline
6th Jan 20258:40 amRNSHoldings in Company
6th Jan 20258:30 amRNSHoldings in Company
9th Dec 20241:30 pmRNSHoldings in Company
9th Dec 20247:00 amRNSTrading Update
5th Dec 20247:00 amRNS$2.7 million Contract Awards
27th Nov 20247:00 amRNSHolding(s) in Company
25th Nov 20247:00 amRNSContract Awards
18th Nov 20247:00 amRNSAppointment of CEO and Award of Options
4th Nov 20247:00 amRNSContract Awards
3rd Oct 20247:00 amRNSHolding(s) in Company
3rd Oct 20247:00 amRNSHolding(s) in Company
2nd Oct 20247:00 amRNSPDMR dealings
16th Sep 20247:00 amRNSTrading Update
9th Sep 20247:00 amRNSUS$3.2 million contract award
4th Sep 20241:30 pmRNSPDMR Dealings
29th Aug 20247:00 amRNSPassing of Paul Webb, Chief Executive Officer
21st Aug 20247:00 amRNSNotifiable Interest in Shares
1st Aug 20241:45 pmRNSHoldings in Company
9th Jul 20244:40 pmRNSHoldings in Company
9th Jul 20247:00 amRNSHalf-year Report
21st Jun 20247:00 amRNSBoard Appointment
18th Jun 20247:00 amRNSUS$10 million contract win
13th Jun 202410:00 amRNSNotice of Investor Presentation
4th Jun 20247:00 amRNSTrading Update
15th May 20247:00 amRNSDirector/PDMR Dealings
24th Apr 202410:00 amRNSResult of AGM
24th Apr 20247:00 amRNSAGM Statement
17th Apr 20247:00 amRNSContract win with a major UK utility provider
9th Apr 20247:00 amRNSBoard Appointment and Grant of Options
3rd Apr 20247:00 amRNSDirector/PDMR Dealings
26th Mar 20247:00 amRNSDirectors / PDMRs' Interests in Shares
26th Mar 20247:00 amRNSDirector/PDMR Shareholding
19th Mar 20247:00 amRNSPosting of Annual Report & Accounts, Notice of AGM
27th Feb 20247:00 amRNSFinal Results
7th Feb 20247:00 amRNSNotice of Results and Investor Presentation
30th Jan 20247:00 amRNSContract Awards
19th Dec 20233:00 pmRNSHolding(s) in Company
11th Dec 20237:00 amRNSTrading Update
29th Nov 20237:00 amRNSContract Win
15th Nov 20237:00 amRNSInvestor Site Visit
23rd Oct 20237:00 amRNSDirectorate Changes
16th Oct 20237:00 amRNSLatest Release of Synectics’ Synergy Software
11th Oct 20237:00 amRNSDirector/PDMR Dealings
28th Sep 20237:00 amRNSAdditional Contract with West Midlands Police
11th Jul 20237:00 amRNSHalf-year Report
4th Jul 20237:00 amRNSContract Award
3rd Jul 20237:00 amRNSInvestor Presentation re interim results
19th Jun 20237:00 amRNSTrading Update and Notification of Results
11th May 20237:00 amRNSDirector dealings
2nd May 20237:00 amRNSNew Gaming Project in Asia

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.